Previous 10 | Next 10 |
CAMBRIDGE, Mass., April 19, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will be participa...
Below is a snapshot of total returns across asset classes using key ETFs traded on US exchanges. For each ETF, we show its total return over the last 12 months, year-to-date through Q1, and in March. In the US, smallcap ETFs like [[IJR]] and [[IWM]] lagged badly in March, and they're only up...
Thinly traded micro cap Constellation Pharmaceuticals ( CNST -1.4% ) slips on average volume in response to results from the Phase 1b portion of a Phase 1/2 clinical trial, ProSTAR , evaluating CPI-1205, combined with Pfizer and Astellas' Xtandi (enzalutamide) or J & J's Zytiga (abi...
Clinical activity of CPI-1205 was seen in subsets of advanced metastatic castration-resistant prostate cancer (mCRPC) patients Recently initiated Phase 2 portion of ProSTAR includes randomized testing of CPI-1205 in combination with enzalutamide versus enzalutamide alone, as well as C...
Constellation Pharmaceuticals (NASDAQ: CNST ): Q4 GAAP EPS of -$0.77 misses by $0.03. More news on: Constellation Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter and full-year 2018 f...
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present...
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jessica Christo has been appointed...
CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the ...
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Scott Braunstein, M.D., has been ap...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...